Omeprazol Zentiva (Omeprazole Sodium)

Omeprazole, the active ingredient in Omeprazol Zentiva, is a proton pump inhibitor (PPI) presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Zentiva is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosive lesions and prevents further damage. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

Omeprazol Zentiva is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: mild bloating. - Constipation: occasional.

Serious or Rare Side Effects: - Clostridioides difficile infection: may present with severe diarrhoea. - Acute interstitial nephritis: renal inflammation. - Severe hypersensitivity reactions: including rash, angio‑edema and anaphylaxis. - Osteoporosis‑related fractures: increased risk with long‑term use. - Vitamin B12 deficiency: may develop after prolonged therapy. - Hepatotoxicity: elevated liver enzymes or hepatitis.

When prescribing Omeprazol Zentiva, clinicians should consider several safety aspects: - Assess the risk of long‑term use including fracture risk and nutrient deficiencies. - Evaluate the need for renal function monitoring in patients with pre‑existing kidney disease. - Review potential drug interactions especially with clopidogrel or warfarin that may require dose adjustment. - Counsel patients on appropriate use and avoidance of over‑the‑counter antacids that may reduce efficacy. - Store at below 25°C: keep in the original pack, protect from moisture.

Omeprazole may interact with several medicines that share metabolic pathways or affect gastric pH.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atorvastatin: increased plasma concentration. - Warfarin: enhanced anticoagulant effect.

Moderate Interactions (Monitor Closely): - Digoxin : increased absorption due to altered pH . - Methotrex t t t t t t. - Sulf   g  g  t  g  t  t. -  g  t.

t.

t  ewline

t  ewline

t  ewline

",